Product Licensing
Jilin Natural Pharmatech Group licenses DiAoNing
Published in Cancer Weekly, July 26th, 2005
Global Pharmatech, Inc., (GBLP), a company which combines R&D of botanical drug products, manufacturing, and sales and marketing for the over-the-counter (OTC) and prescription drug markets, announced that Jilin Natural Pharmatech Group Co., Ltd., a company wholly owned by Global Pharmatech, Inc., signed a technology transfer agreement with Changchun XinYu Pharmaceutical Co., Ltd., (XinYu) to license its newly developed R&D drug product, DiAoNing.
The R&D licensing agreement totals 8.3 million Ren Min Bi to be paid in several installments of which approximately 85% will be paid by XinYu within the next 12 months. The remaining balance will then be paid upon the drug...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2005-07-26)
More Articles from Cancer Weekly
- Cancer Risk Factors
Associated nutritional risk of breast and colon cancers disproved - Cancer Survival
Personality not associated with cancer survival - Lung Cancer
NAT2 genotype associated with increased risk of lung cancer among never-smokers - Mental Illness
Adolescents' perception of stigma of mental illness and alcohol abuse reviewed - Adenovirus
Adenovirus examined, E1B-AP5 interaction with p53 reported - Advocacy
Lung cancer nonprofit program launches newly redesigned Internet site - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
